Navigation Links
Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
Date:7/26/2010

class="xn-location">Europe to make affordable, safe and effective biosimilars available to U.S. patients and their healthcare providers once patents expire over the next several years."

Hospira already sells a biosimilar EPO in Europe, Retacrit™, and is the first U.S.-headquartered company with biosimilars on the European market. Retacrit, introduced in early 2008, now has a more than 50 percent share of the total short-acting EPO biosimilar market in Europe. In addition, Hospira recently launched Nivestim™, a biosimilar version of filgrastim, in the United Kingdom, Germany and Ireland. Filgrastim is a granulocyte colony-stimulating factor (G-CSF) used to treat neutropenia, a condition in which the body makes too few infection-fighting white blood cells. The condition is often caused by drugs prescribed for cancer treatment.

Hospira's Phase I study is being conducted with the participation of DaVita Inc. (NYSE: DVA), and Fresenius Medical Care AG & Co. KGaA (NYSE: FMS, FMS/P). Although Phase I trials are most often conducted with healthy volunteers, Hospira received U.S. Food and Drug Administration (FDA) approval to conduct its Phase I trial with patients.

Biosimilars are high-quality, cost-effective alternatives to proprietary biopharmaceuticals, which are large-protein molecules derived from genetically modified cell lines. In contrast, "traditional" pharmaceuticals are made from small-molecule, chemical substances. With a growing number of patents for biopharmaceuticals expiring, Hospira has significantly expanded its comprehensive competencies to develop, manufacture and ma
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections
2. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
3. Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.)
4. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
5. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
6. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
7. Hospira to Present at Citi 2010 Global Health Care Conference May 27, 2010
8. Hospira Supports Disaster Relief Efforts in Haiti With Products and Cash Grants
9. Hospira to Present at J.P. Morgan 28th Annual Healthcare Conference Jan. 13, 2010
10. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
11. Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Surgical Company (NASDAQ: STAA ) a leading ... systems for the eye today reported revenue for the ... a 10% increase over $18.2 million reported for the ... revenues grew 11% during the second quarter of 2014 ... of foreign currency exchange reduced sales by $0.1 million ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
... Wash., Feb. 21, 2011 Royal Philips Electronics NV ... MSFT ) today announced the companies will collaborate ... to build and understand the complete clinical context of ... commitment to work together to connect technologies that will ...
... Medical, Inc. (Nasdaq: NXTM ), a leading ... recent independent study which reports that home hemodialysis with ... carbon footprint of therapy conducted with traditional in-center hemodialysis ... delivering superior clinical results is a core competency of ...
Cached Medicine Technology:Philips and Microsoft Collaborate to Streamline Radiology Workflow and Processes 2Philips and Microsoft Collaborate to Streamline Radiology Workflow and Processes 3Independent Study Reports 50% Smaller Carbon Footprint With NxStage System One™ vs. Standard In-Center Hemodialysis Machines 2Independent Study Reports 50% Smaller Carbon Footprint With NxStage System One™ vs. Standard In-Center Hemodialysis Machines 3
(Date:8/1/2014)... Did you know that July was ... is to raise awareness across the country and to educate ... According to the American Cancer Society, nearly 5,000 Americans are ... new soft tissue sarcomas will be diagnosed. , “A ... they are other kinds of cancer,” said Dr. Chawla, a ...
(Date:8/1/2014)... “When insulation goes bad,” Clean Crawls says, “It ... newly released article entitled, “ 5 Signs That Your ... ,” Clean Crawls explains the need to replace insulation ... critters. , Get a free attic insulation or ... http://www.cleancrawl.com/contact . , If crawl space or attic insulation ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 According to the ... is a comprehensive diet guide for women who want to ... list of protein rich foods and fat loss ... muscle mass. , Vkool writes in its review that this ... the truth about fat burning hormones and weight loss supplements. ...
(Date:8/1/2014)... 2014 The Multiple System Atrophy Coalition, a ... caregivers and families affected by the neurological disorder Multiple System ... La Coste, TX to its Board of Directors. , Sharon ... Eric Sutton. He was diagnosed officially with MSA in 2010 ... his family. Like many others with this rare disorder it ...
(Date:8/1/2014)... WA (PRWEB) August 01, 2014 Blindness is ... be argued that the scientists of today, despite well-meaning efforts, ... to providing a definite treatment for reversing blindness that does ... that sense, this is where alternative medicine takes the “slack” ... rely on expensive treatments or harmful surgeries. , Alternative ...
Breaking Medicine News(10 mins):Health News:July Was Sarcoma Awareness Month! 2Health News:July Was Sarcoma Awareness Month! 3Health News:July Was Sarcoma Awareness Month! 4Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 3Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 3Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2
... Cloning Livestock From,Differentiated Donor Cells, AUSTIN, Texas, ... that the U.S. Patent and Trademark Office has,granted ... of,cloning ungulate animals, fetuses and embryos using differentiated ... of patents and patent,applications owned by Roslin Institute ...
... N.C., Dec. 11 Quintiles,Transnational Corp. today announced ... and General Counsel., Previously Senior Vice President, ... in 1998 as Vice President, European,Legal Affairs., ... the clinical,research industry, having served the company in ...
... Brings More Than 30 Years Experience to ... Personal Therapeutic Device Leader, ... INCR) manufacturer of the RESPeRATE(R) hypertension treatment,device, clinically-proven to significantly ... Vice President of Sales. Dube,brings more than 30 years of ...
... WILLIAMSVILLE, N.Y., Dec. 11 The office of,Congressman ... Leadership,Award for voting against huge cuts in Medicare ... Reynolds received the award from The,Coalition for Medicare ... strengthen Medicare Choices., David Trumpfheller, Coalition Member ...
... Amedica Corporation, an,orthopedic implants company focused on silicon ... and Drug Administration,has granted a Special 510(k) marketing ... The Valeo VBR spinal implant is intended for ... stabilization of the thoracolumbar spine.,The Valeo VBR incorporates ...
... Valued at Over $96,000, LIVINGSTON, N.J., Dec. ... announced today that its wholly-owned,subsidiary, Genotec Nutritionals, Inc., ... sales from the distribution of its branded,products and ... closed on a large order for a new ...
Cached Medicine News:Health News:Start Licensing, Inc. Further Strengthens Position in Cloning Industry With New Patents 2Health News:InterCure Names Scot Dube Vice President of Sales 2Health News:InterCure Names Scot Dube Vice President of Sales 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:MM2 Group Closes Sale for New Fish Oil Product 2Health News:MM2 Group Closes Sale for New Fish Oil Product 3
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
... EDS 3 CSF External Drainage System was developed ... physicians. The clinicians who work every day with ... EDS 3: ease-of-use in an integrated pole clamp, ... accurate hydrostatic leveling from a unique laser leveling ...
... Trippi-Wells and Universal tongs were developed for ... than can be safely provided for with ... construction. Kit complete with four skull pins ... pin application. Skull pins at 10 angle. ...
Cruchfield Skull Traction Tong, small pattern....
Medicine Products: